New study drug compared with metoprolol for hypertrophic cardiomyopathy
Treatments studied
Part of Heart & circulation clinical trials.
This trial compares a new study drug (BHB-1893) with a standard heart medication called metoprolol to see which one better improves symptoms in people with obstructive hypertrophic cardiomyopathy. If you join, you will be randomly assigned to receive either the study drug or metoprolol, and your symptoms and heart function will be monitored over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (a heart condition where the heart muscle is thickened and blocks blood flow).
- You experience symptoms like chest pain, shortness of breath, or fatigue during everyday activities (NYHA class II or III).
- Your heart ultrasound (echocardiogram) can clearly show the heart structures, and your symptoms meet a specific quality-of-life score.
- You are not currently taking beta-blockers or calcium-channel blockers for other reasons, and you have not had a bad reaction to beta-blockers in the past.
- Your resting blood pressure is not too high (under 160 mmHg) and your resting heart rate is not too fast (under 100 beats per minute).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
This study tests whether two common heart medicines, bisoprolol and verapamil, improve symptoms in adults with non-obstructive hypertrophic cardiomyopathy. It may help you and your care team understand which medicine works better for symptom control and heart function.
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
This study follows people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens, to learn more about how it affects them in real life. It may help doctors better understand and manage the condition.
This trial tests an investigational drug given as an injection under the skin for people with a type of hypertrophic cardiomyopathy that does not block blood flow out of the heart. The goal is to see if the drug is safe and may help improve symptoms.
This study tests an experimental medication called Aom0304 for adults with symptomatic hypertrophic cardiomyopathy (a condition where the heart muscle is abnormally thick). The goal is to see if it helps reduce symptoms and improve heart function.
Hear when a new Cardiomyopathy, Hypertrophic Obstructive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.